"When a generic drug company carves a patented use out of its label but then markets the product as the full equivalent of the brand, who bears responsibility for the infringement that inevitably follows? The Supreme Court will answer that question this Term in Hikma v. Amarin - a case that will shape the future of generic drug competition and the value of method-of-use patents."
"Some markets are tinderboxes. These are structurally primed for infringement based upon automatic substitution laws and therapeutic equivalence ratings. In these markets, promotional conduct that would be innocuous elsewhere becomes the spark that ignites widespread infringement. One way to see the debate is to ask whether widespread skinny-label infringement is a system feature or a bug."
"The essay also looks at inducement causation and argues that strict "but for" causation would perversely immunize intentional inducement in the most infringement-prone markets, because in those markets the infringement would occur regardless of the defendant's specific promotional efforts."
The Supreme Court case Hikma v. Amarin addresses when generic drug manufacturers cross the line into actively inducing infringement of brand-name method-of-use patents. The case involves generic companies that remove patented uses from drug labels but market products as full equivalents to branded versions. A working paper proposes a framework analyzing this issue through market structure dynamics, arguing that certain markets are structurally primed for infringement due to automatic substitution laws and therapeutic equivalence ratings. The analysis distinguishes between promotional conduct that would be innocuous in other contexts but becomes problematic in these "tinderbox" markets. The framework also examines inducement causation, suggesting strict "but for" causation standards could paradoxically immunize intentional inducement in high-infringement-risk markets.
Read at Patently-O
Unable to calculate read time
Collection
[
|
...
]